Towards improved treatment for refractory breathlessness
Chronic breathlessness (CB) is a frightening disease associated with physical and psychosocial morbidities. Since there are few effective drug treatments, CB causes severe patient and family distress. The EU-funded BETTER-B project is testing whether mirtazapine, an established antidepressant, could be used to treat CB as suggested by a recent feasibility study. BETTER-B researchers will conduct a randomised double-blind clinical trial to test the effectiveness and cost-effectiveness of mirtazapine versus placebo in patients in different European countries. The project also includes an online survey of physicians, production of Europe-wide guidance on breathlessness management in palliative and end-of-life care, and qualitative interviews with trial participants to understand their experiences.
Call for proposal
See other projects for this call
Funding SchemeRIA - Research and Innovation action
42100 Reggio Emilia